Get started

Financials · NEO

NeoGenomics Inc. (NEO) financials

For the twelve months ended Sep 30, 2026, NeoGenomics Inc. reported $787.75M of revenue and -$32.30M of net income.

Revenue, TTM
$787.75M
Revenue growth, YoY
+11.1%
Net income, TTM
-$32.30M
Net margin
-4.1%
Free cash flow, TTM
-$28.58M
EPS, diluted, TTM
-$0.25
Cash
$139.28M
Total debt
$374.69M
P/S
2.89
Market cap
$2.28B
Annual revenue$727.33M
FY2016FY2025
Annual net income-$108.03M
FY2016FY2025
Annual free cash flow-$21.78M
FY2016FY2025

NEO revenue and earnings growth

NEO revenueQ3 2026$209.25M

Quarter YoY
+11.4%
QoQ
+3.8%
FY YoY
+10.1%
5Y CAGR
+10.4%

NEO revenue was $209.25M in fiscal Q3 2026 (ended Sep 30, 2026), up 11.4% from a year earlier and up 3.8% from the prior quarter. For the full fiscal 2025 it was $727.33M, up 10.1% from fiscal 2024. Compound annual growth was +10.4% over 5 years. It rose in each of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

NEO net incomeQ3 2026-$7.55M

NEO net income was -$7.55M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$27.13M a year earlier. For the full fiscal 2025 it was -$108.03M, compared with -$78.73M in fiscal 2024.

NEO EPSQ3 2026-$0.06

NEO diluted EPS was -$0.06 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2025 it was -$0.84, compared with -$0.62 in fiscal 2024.

NEO free cash flowQ3 2026-$20.66M

NEO free cash flow was -$20.66M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $570.0K a year earlier. For the full fiscal 2025 it was -$21.78M, compared with -$34.04M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$727.33M$660.57M$591.64M$509.73M$484.33M$444.45M$408.83M$276.74M$240.25M$231.81M
Cost of revenue$413.04M$370.47M$347.04M$321.83M$297.27M$258.56M$211.99M$149.48M$138.29M$133.70M
Gross profit$314.29M$290.10M$244.60M$187.90M$187.06M$185.89M$196.84M$127.27M$101.96M$98.10M
Research and development$37.08M$31.16M$27.31M$30.33M$21.87M$8.23M$8.49M$3.00M$3.64M$4.65M
Selling, general and admin$273.34M$259.74M$243.10M$243.36M$221.35M$143.79M$127.99M$84.82M$70.36M$63.93M
Operating income-$115.88M-$92.11M-$107.74M-$157.62M-$118.75M-$13.99M$13.01M$10.04M$2.90M$2.15M
Interest expense$3.75M$6.62M$6.91M$7.58M$8.22M$7.02M$3.71M$6.23M$5.54M-
Pre-tax income-$110.27M-$80.67M-$97.10M-$159.34M-$15.07M-$14.06M$3.65M$3.82M-$2.65M-$7.84M
Income tax-$2.24M-$1.95M-$9.13M-$15.09M-$6.73M-$18.23M-$4.36M$1.18M-$2.25M-$1.70M
Net income-$108.03M-$78.73M-$87.97M-$144.25M-$8.35M$4.17M$8.01M$2.64M-$396.0K-$6.14M
EPS, basic-$0.84-$0.62-$0.70-$1.16-$0.07$0.04$0.08$0.07-$0.14-$0.40
EPS, diluted-$0.84-$0.62-$0.70-$1.16-$0.07$0.04$0.08$0.07-$0.14-$0.40
Diluted shares128.1M126.7M125.5M124.2M120.0M111.8M103.6M91.6M79.4M77.5M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$159.62M$367.01M$342.49M$263.18M$316.83M$250.63M$173.02M$9.81M$12.82M$12.53M
Receivables$159.24M$150.54M$131.23M$119.71M$112.13M$106.84M$94.24M$76.92M$60.43M$55.51M
Inventory$28.57M$26.75M$24.16M$24.28M$23.39M$29.53M$14.40M$8.65M$7.47M$6.25M
Current assets$376.29M$596.02M$596.81M$605.29M$681.51M$448.73M$290.74M$103.67M$85.88M$78.83M
Goodwill$524.34M$522.77M$522.77M$522.77M$527.12M$211.08M$198.60M$197.89M$147.02M$147.02M
Total assets$1.36B$1.64B$1.68B$1.74B$1.87B$988.33M$709.51M$505.01M$344.45M$337.12M
Current liabilities$88.30M$301.24M$96.30M$89.93M$87.23M$73.18M$63.90M$60.92M$36.47M$38.11M
Short-term debt$0$200.78M---$0$5.00M$7.87M$3.75M$3.75M
Long-term debt$341.86M$340.33M$538.20M$535.32M$532.55M$169.09M$95.03M$98.13M$96.44M$97.44M
Total debt$341.86M$541.11M$538.20M$535.32M$532.55M$169.09M$100.03M$106.00M$100.19M$101.19M
Total liabilities$523.27M$735.70M$739.69M$742.01M$761.50M$294.04M$202.10M$184.57M$139.88M$150.52M
Shareholders' equity$836.56M$902.34M$941.54M$998.02M$1.11B$694.29M$507.41M$320.44M$171.96M$162.32M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$5.23M$7.02M-$1.95M-$65.99M-$26.72M$1.46M$23.37M$44.79M$18.04M$21.48M
Capital expenditures$27.01M$41.06M$28.75M$30.89M$64.14M$29.10M$20.03M$14.31M$13.69M$7.54M
Free cash flow-$21.78M-$34.04M-$30.70M-$96.88M-$90.86M-$27.64M$3.34M$30.48M$4.35M$13.94M
Investing cash flow-$12.34M$12.86M$76.71M$517.0K-$632.37M-$159.44M-$19.63M-$139.69M-$13.69M-$6.50M
Financing cash flow-$200.29M$4.65M$4.55M$11.83M$725.28M$235.60M$159.47M$91.96M-$4.09M-$25.87M
Stock-based compensation$41.32M$33.41M$24.63M$24.67M$22.46M$10.21M$10.00M$6.96M$6.44M$5.44M
Depreciation and amortization-----$25.90M$20.35M$15.80M$15.60M$15.94M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY10.1%11.6%16.1%5.2%9.0%8.7%47.7%15.2%3.6%-
Net income growth, YoY------47.9%203.3%---
EPS growth, YoY------50.0%14.3%---
Gross margin43.2%43.9%41.3%36.9%38.6%41.8%48.1%46.0%42.4%42.3%
Operating margin-15.9%-13.9%-18.2%-30.9%-24.5%-3.1%3.2%3.6%1.2%0.9%
Net margin-14.9%-11.9%-14.9%-28.3%-1.7%0.9%2.0%1.0%-0.2%-2.6%
Free cash flow margin-3.0%-5.2%-5.2%-19.0%-18.8%-6.2%0.8%11.0%1.8%6.0%
Return on equity-12.9%-8.7%-9.3%-14.5%-0.8%0.6%1.6%0.8%-0.2%-3.8%
Return on assets-7.9%-4.8%-5.2%-8.3%-0.4%0.4%1.1%0.5%-0.1%-1.8%
Current ratio4.261.986.206.737.816.134.551.702.352.07
Debt to equity0.410.600.570.540.480.240.200.330.580.62

Source: XBRL data NeoGenomics Inc. files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NEO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
NEO$787.75M+11.1%-$32.30M-4.1%$2.28B
ULS$3.19B+6.1%$513.00M16.1%$16.39B
AIDX$2.05M+16.7%-$3.74M-182.8%$2.6M

NEO FAQ

9 questions
  • What is NEO revenue?
    NeoGenomics Inc. (NEO) reported $787.75M of revenue for the twelve months ended Sep 30, 2026. That is up 11.1% from the year before. Revenue for fiscal 2025 was $727.33M.
  • Is NEO profitable?
    No. NeoGenomics Inc. reported a net loss of $32.30M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does NEO have?
    NeoGenomics Inc. reported $139.28M in cash and cash equivalents and $374.69M of debt on its most recent balance sheet in SEC filings.
  • How fast is NEO revenue growing?
    NeoGenomics Inc.'s revenue changed +10.1% in fiscal 2025, to $727.33M. Its compound annual growth rate was +10.4% over 5 years.
  • What is NEO gross margin?
    NeoGenomics Inc.'s gross profit was $352.67M on $787.75M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 44.8%.
  • What is NEO free cash flow?
    NeoGenomics Inc. generated -$28.58M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $4.28M less capital expenditures.
  • What is NEO earnings per share?
    Diluted earnings per share were -$0.25 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did NEO last report financial results?
    The latest statements here come from NeoGenomics Inc.'s 10-Q filed on Oct 28, 2026, covering the period ended Sep 30, 2026.
  • Where does this NEO financial data come from?
    Quantisnow builds these statements from the structured XBRL data NeoGenomics Inc. files with the SEC. It is provided for information only and is not investment advice.